PPARs at the crossroads of lipid signaling and inflammation

Trends in Endocrinology and Metabolism

Volumn 23, Issue 7, 2012, Pages 351-363

  Wahli, Walter ^a   Michalik, Liliane ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; AJULEMIC ACID; ANTIINFLAMMATORY AGENT; ARACHIDIC ACID; CELL SURFACE RECEPTOR; CEVOGLITAZAR; CG 301269; CG301269; CP 900691; CP900691; FATTY ACID; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 4; LIGAND; LIPID; LYSOPHOSPHATIDIC ACID; MBX 8025; MBX8025; MESALAZINE; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; POLYUNSATURATED FATTY ACID; PROSTACYCLIN; SR 1664; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL SURFACE; CONGESTIVE HEART FAILURE; CROHN DISEASE; DYSLIPIDEMIA; ENTERITIS; FRACTURE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WEIGHT GAIN;

ANIMALS; HUMANS; INFLAMMATION; LIPID METABOLISM; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 84863104065     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.05.001     Document Type: Review

References (114)

1. Calder P.C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 2006, 83:1505S-1519S.
2. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 2009, 49:123-150.
3. Stables M.J., Gilroy D.W. Old and new generation lipid mediators in acute inflammation and resolution. Prog. Lipid Res. 2011, 50:35-51.
4. Haeggstrom J.Z., Funk C.D. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem. Rev. 2011, 111:5866-5898.
5. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
6. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
7. Talukdar S., et al. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol. Sci. 2011, 32:543-550.
8. Dasu M.R., et al. Toll-like receptors and diabetes: a therapeutic perspective. Clin. Sci. 2012, 122:203-214.
9. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007, 28:551-558.
10. Varga T., et al. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim. Biophys. Acta 2011, 1812:1007-1022.
11. Michalik L., et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58:726-741.
12. Coleman J.D., et al. The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Free Radic. Biol. Med. 2007, 42:1155-1164.
13. Riahi Y., et al. The natural protective mechanism against hyperglycemia in vascular endothelial cells: roles of the lipid peroxidation product 4-hydroxydodecadienal and peroxisome proliferator-activated receptor delta. Diabetes 2010, 59:808-818.
14. Schupp M., Lazar M.A. Endogenous ligands for nuclear receptors: digging deeper. J. Biol. Chem. 2010, 285:40409-40415.
15. Clementi A.H., et al. Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling. Biochim. Biophys. Acta 2009, 1792:1062-1072.
16. Evans R.M., et al. PPARs and the complex journey to obesity. Nat. Med. 2004, 10:355-361.
17. Odegaard J.I., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
18. Hevener A.L., et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 2007, 117:1658-1669.
19. Kersten S. Regulation of nutrient metabolism and inflammation. Results Probl. Cell Differ. 2010, 52:13-25.
20. Michalik L., Wahli W. PPARs mediate lipid signaling in inflammation and cancer. PPAR Res. 2008, 2008:134059.
21. Bishop-Bailey D., Bystrom J. Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation. Pharmacol. Ther. 2009, 124:141-150.
22. Devchand P.R., et al. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996, 384:39-43.
23. Narala V.R., et al. Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist. J. Biol. Chem. 2010, 285:22067-22074.
24. Delerive P., et al. DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol. Endocrinol. 2002, 16:1029-1039.
25. Stienstra R., et al. The interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver. J. Hepatol. 2007, 46:869-877.
26. Leuenberger N., et al. Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice. J. Clin. Invest. 2009, 119:3138-3148.
27. Poulsen L.L., et al. PPARs: fatty acid sensors controlling metabolism. Semin. Cell Dev. Biol. 2012, 10.1016/j.semcdb.2012.01.003.
28. Bougarne N., et al. PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7397-7402.
29. Crisafulli C., et al. PPAR-alpha contributes to the anti-inflammatory activity of 17beta-estradiol. J. Pharmacol. Exp. Ther. 2009, 331:796-807.
30. Lichtenstein L., et al. Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 2010, 12:580-592.
31. Huang W., Glass C.K. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1542-2159.
32. Pascual G., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
33. Wan Y., et al. Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk. Genes Dev. 2007, 21:1895-1908.
34. Fresno M., et al. Toll-like receptors, inflammation, metabolism and obesity. Arch. Physiol. Biochem. 2011, 117:151-164.
35. Yessoufou A., et al. Peroxisome proliferator-activated receptor-alpha modulates insulin gene transcription factors and inflammation in adipose tissues in mice. Mol. Cell. Biochem. 2009, 323:101-111.
36. + effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 2009, 15:914-920.
37. Patsouris D., et al. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008, 8:301-309.
38. Wu D., et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011, 332:243-247.
39. Rodriguez-Calvo R., et al. Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes 2008, 57:2149-2157.
40. Stienstra R., et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 2010, 51:511-522.
41. Huang W., et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 2010, 59:347-357.
42. Shan W., et al. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology 2008, 47:225-235.
43. Odegaard J.I., et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008, 7:496-507.
44. Hellemans K., et al. Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 2003, 124:184-201.
45. Moran-Salvador E., et al. Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J. 2011, 25:2538-2550.
46. Babaev V.R., et al. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007, 116:1404-1412.
47. Mansouri R.M., et al. Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response. Endocrinology 2008, 149:3215-3223.
48. Zhou J., et al. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10355-10360.
49. -/- mice. Atherosclerosis 2005, 181:29-37.
50. Lee C.H., et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 2003, 302:453-457.
51. Takata Y., et al. PPARdelta-mediated anti-inflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4277-4282.
52. Hamblin M., et al. Vascular smooth muscle cell peroxisome proliferator-activated receptor-gamma mediates pioglitazone-reduced vascular lesion formation. Arterioscler. Thromb. Vasc. Biol. 2011, 31:352-359.
53. Babaev V.R., et al. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1647-1653.
54. Qu A., et al. Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null Mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32:65-73.
55. Henique C., et al. Increased mitochondrial fatty acid oxidation is sufficient to protect skeletal muscle cells from palmitate-induced apoptosis. J. Biol. Chem. 2010, 285:36818-36827.
56. Coll T., et al. Oleate reverses palmitate-induced insulin resistance and inflammation in skeletal muscle cells. J. Biol. Chem. 2008, 283:11107-11116.
57. Kramer D.K., et al. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J. Biol. Chem. 2007, 282:19313-19320.
58. Coll T., et al. Activation of peroxisome proliferator-activated receptor-δ by GW501516 prevents fatty acid-induced nuclear factor-κB activation and insulin resistance in skeletal muscle cells. Endocrinology 2010, 151:1560-1569.
59. Salvado L., et al. Targeting PPARbeta/delta for the treatment of type 2 diabetes mellitus. Expert Opin. Ther. Targets 2012, 16:209-223.
60. Gan Z., et al. The nuclear receptor PPARbeta/delta programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes Dev. 2011, 25:2619-2630.
61. Smeets P.J., et al. Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta. J. Biol. Chem. 2008, 283:29109-29118.
62. Planavila A., et al. Sirt1 acts in association with PPARalpha to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc. Res. 2011, 90:276-284.
63. Ding G., et al. PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J. Mol. Cell. Cardiol. 2006, 40:821-828.
64. Alvarez-Guardia D., et al. PPARbeta/delta activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochim. Biophys. Acta 2011, 1811:59-67.
65. Caglayan E., et al. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes 2008, 57:2470-2479.
66. Dubuquoy L., et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003, 124:1265-1276.
67. Poliska S., et al. Association of peroxisome proliferator-activated receptor gamma polymorphisms with inflammatory bowel disease in a Hungarian cohort. Inflamm. Bowel Dis. 2012, 18:472-479.
68. Aoyagi Y., et al. Peroxisome proliferator-activated receptor gamma 2 mutation may cause a subset of ulcerative colitis. Pediatr. Int. 2010, 52:729-734.
69. Peyrin-Biroulet L., et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8772-8777.
70. Marion-Letellier R., et al. Dietary modulation of peroxisome proliferator-activated receptor gamma. Gut 2009, 58:586-593.
71. Hollingshead H.E., et al. PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism. Dig. Dis. Sci. 2007, 52:2912-2919.
72. Lee J.W., et al. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. Gastroenterology 2007, 133:108-123.
73. Varnat F., et al. PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology 2006, 131:538-553.
74. Cuzzocrea S., et al. Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. Lab. Invest. 2004, 84:1643-1654.
75. Azuma Y.T., et al. PPARalpha contributes to colonic protection in mice with DSS-induced colitis. Int. Immunopharmacol. 2010, 10:1261-1267.
76. Pirat C., et al. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. J. Med. Chem. 2012, 55:4027-4061.
77. O'Sullivan S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol. 2007, 152:576-582.
78. Rousseaux C., et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J. Exp. Med. 2005, 201:1205-1215.
79. Choi J.H., et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 2011, 477:477-481.
80. Li P., et al. Adipocyte NCoR knockout decreases PPARgamma phosphorylation and enhances PPARgamma activity and insulin sensitivity. Cell 2011, 147:815-826.
81. Daynes R.A., Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2002, 2:748-759.
82. Mohapatra S.K., et al. Immunoregulatory actions of epithelial cell PPAR gamma at the colonic mucosa of mice with experimental inflammatory bowel disease. PLoS ONE 2010, 5:e10215.
83. Ban K., et al. Glutamine activates peroxisome proliferator-activated receptor-gamma in intestinal epithelial cells via 15-S-HETE and 13-OXO-ODE: a novel mechanism. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G547-G554.
84. Wagner J.D., et al. A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys. J. Pharmacol. Exp. Ther. 2010, 333:844-853.
85. Pace E., et al. Pleural mesothelial cells express both BLT2 and PPARalpha and mount an integrated response to pleural leukotriene B4. J. Immunol. 2008, 181:7292-7299.
86. Paruchuri S., et al. Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J. Biol. Chem. 2008, 283:16477-16487.
87. Yousefipour Z., et al. Role of G protein-coupled receptor kinase-2 in peroxisome proliferator-activated receptor gamma-mediated modulation of blood pressure and renal vascular reactivity in SHR. Am. J. Nephrol. 2009, 30:201-208.
88. Hong Y.H., et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology 2005, 146:5092-5099.
89. McIntyre T.M., et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:131-136.
90. Liliom K., et al. Farnesyl phosphates are endogenous ligands of lysophosphatidic acid receptors: inhibition of LPA GPCR and activation of PPARs. Biochim. Biophys. Acta 2006, 1761:1506-1514.
91. Eun C.S., et al. Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway. Dig. Dis. Sci. 2006, 51:693-697.
92. Voltan S., et al. Lactobacillus crispatus M247-derived H2O2 acts as a signal transducing molecule activating peroxisome proliferator activated receptor-gamma in the intestinal mucosa. Gastroenterology 2008, 135:1216-1227.
93. Tezera L.B., et al. Neisseria lactamica attenuates TLR-1/2-induced cytokine responses in nasopharyngeal epithelial cells using PPAR-gamma. Cell. Microbiol. 2011, 13:554-568.
94. Appel S., et al. PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood 2005, 106:3888-3894.
95. Dasu M.R., et al. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009, 150:3457-3464.
96. Zhao W., et al. Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-beta promoter. J. Biol. Chem. 2011, 286:5519-5528.
97. Ogawa S., et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122:707-721.
98. Almeida P.E., et al. Mycobacterium bovis bacillus Calmette-Guérin infection induces TLR2-dependent peroxisome proliferator-activated receptor gamma expression and activation: functions in inflammation, lipid metabolism, and pathogenesis. J. Immunol. 2009, 183:1337-1345.
99. Hanley T.M., Viglianti G.A. Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms. J. Virol. 2011, 85:10834-10850.
100. Wu Y., et al. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced Toll-like receptor 4 expression in vascular smooth muscle cells. Brain Res. 2010, 1322:102-108.
101. Wu Y., et al. Therapeutic potential of peroxisome proliferator-activated receptor gamma agonist rosiglitazone in cerebral vasospasm after a rat experimental subarachnoid hemorrhage model. J. Neurol. Sci. 2011, 305:85-91.
102. Adachi M., et al. Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 2006, 55:1104-1113.
103. Bassaganya-Riera J., et al. Activation of PPARgamma and delta by dietary punicic acid ameliorates intestinal inflammation in mice. Br. J. Nutr. 2011, 106:878-886.
104. Shah Y.M., et al. Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G657-G666.
105. Hontecillas R., et al. Immunoregulatory mechanisms of macrophage PPAR-gamma in mice with experimental inflammatory bowel disease. Mucosal Immunol. 2011, 4:304-313.
106. Guri A.J., et al. The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol. 2010, 10:60.
107. Guri A.J., et al. T cell PPARgamma is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD. J. Nutr. Biochem. 2011, 22:812-819.
108. Bays H.E., et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J. Clin. Endocrinol. Metab. 2011, 96:2889-3897.
109. Rousseaux C., et al. Preclinical and toxicological assessments of novel orally bioavailable PPAR ligand GED-0507-34-Levo for the treatment of inflammatory bowel disease. Gastroenterology 2010, 138:S-157.
110. Chen H., et al. Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys. Endocrinology 2010, 151:3115-3124.
111. Laurent D., et al. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. Diabetes Obes. Metab. 2009, 11:632-636.
112. Jeong H.W., et al. A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma. Diabetes 2011, 60:496-506.
113. Liu J., et al. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol. Pharmacol. 2003, 63:983-992.
114. Zurier R.B., et al. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB J. 2009, 23:1503-1509.